An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Nosocomial Genotype 1 HCV Infection
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2015
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 06 Oct 2015 Primary endpoint has been met. (Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12))
- 06 Oct 2015 Results published online in Antiviral Therapy.
- 20 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.